Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
Status:
Completed
Trial end date:
2018-08-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo
in patients with high cardiovascular risk and elevated LDL cholesterol not adequately
controlled by their current therapy.